<DOC>
	<DOCNO>NCT00692913</DOCNO>
	<brief_summary>A study design see study drug increase blood level vitamin D , bone mineral density ( BMD ) , improve biochemical marker bone turnover , reduce number fall compare woman receive standard care osteoporosis .</brief_summary>
	<brief_title>A Study Test Effect MK0217A Vitamin D Inadequacy Postmenopausal Women With Osteoporosis ( 0217A-262 )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Female 65 year old Diagnosed osteoporosis ( Bone Mineral Density ( BMD ) Tscore &lt; = 2.5 spine hip ) prior fragility fracture BMD Tscore &lt; =1.5 least one anatomic sit include lumbar spine , total hip , femoral neck site Postmenopausal Low level vitamin D measure 25hydroxyvitamin D Has fall least within past 12 month Unable stand sit upright least 30 minute Has bone disorder osteoporosis Contraindication use FOSAVANCE</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>